- Details
- Ashish Kamat interviews Shilpa Gupta about the best of ASCO 2024 in advanced bladder cancer. Dr. Gupta discusses three abstracts: the CheckMate-901 trial's analysis of complete responders to Nivolumab plus gemcitabine-cisplatin in lymph node-only metastatic urothelial cancer; patient-reported outcomes from the EV-302 trial comparing enfortumab vedotin plus pembrolizumab to platinum chemotherapy; a...
|
- Details
- Ashish Kamat interviews Omar Alhalabi about research on small cell neuroendocrine carcinoma of the urinary tract. Dr. Alhalabi discusses the study's findings on prognostic factors for relapse in surgically resected cases. The research reveals that neoadjuvant chemotherapy benefits patients, while the persistence of small cell carcinoma at surgery is associated with a high risk of relapse. The stud...
|
- Details
- Sam Chang interviews Elias Chandran about a systematic review and meta-analysis on mismatch repair deficiency (dMMR) and microsatellite instability (MSI-H) in urothelial carcinoma. Dr. Chandran presents findings showing higher prevalence of dMMR and MSI-H in upper tract urothelial carcinoma compared to bladder cancer, with greater frequency in localized disease than metastatic disease. The study s...
|
- Details
- Sam Chang and Bernard Bochner discuss a novel antibody treatment targeting the CD40 receptor for non-muscle invasive bladder cancer resistant to BCG therapy. Dr. Bochner presents findings from a phase one study showing promising results with minimal toxicity. The treatment activates dendritic cells, leading to CD8+ T cell recruitment and tumor elimination. Preliminary data indicates a 50% complete...
|
- Details
- Ashish Kamat hosts Giuseppe Simone to discuss a randomized trial that compares robotic-assisted radical cystectomy with completely intracorporeal urinary diversion to the traditional open approach. Published three-year outcomes demonstrate a notable reduction in preoperative transfusion rates for the robotic approach, though costs were higher due to surgical devices. Functional outcomes such as ni...
|
- Details
- Ashish Kamat introduces Armine Smith to discuss the intricacies of treating female bladder cancer, emphasizing organ and sexual function preservation during radical cystectomy. Highlighting a groundbreaking course at the AUA, Professor Smith explores significant topics like patient selection, operative techniques, and postoperative care. The course, a first of its kind, addresses the disparities i...
|
- Details
- Sam Chang interviews Sunil Patel about the Orion Bladder Cancer Study. The phase 3 single-arm study evaluates the efficacy and safety of a paclitaxel-hyaluronic acid conjugate, ONCOFID-P-B, administered intravesically for patients with BCG-unresponsive CIS of the bladder. This novel agent targets CD44, overexpressed in bladder cancer cells, and has shown promising results with a high complete resp...
|
- Details
- Sam Chang hosts Amanda Myers and Tim Lyon to discuss the burdens of intravesical therapy for bladder cancer. Dr. Myers shares insights from their study on the patient-reported treatment burdens, revealing significant challenges related to travel, cost, and daily life disruptions due to the current clinic-based treatment setup. The study suggests a strong patient interest in transitioning to in-hom...
|
- Details
- Ashish Kamat engages with Andrea Necchi about the use of next-generation sequencing (NGS) in urothelial carcinoma. Dr. Necchi highlights consensus recommendations from a recent retreat, emphasizing the importance of NGS in identifying actionable mutations across different stages of bladder cancer. He underscores the need for careful tissue management, recommending NGS especially when clinical tria...
|
- Details
- Sam Chang interviews Roger Li about the MoonRISe-1 trial. This phase 3 study explores the use of TAR-210, an innovative intravesical delivery system for the tyrosine kinase inhibitor erdafitinib, targeting patients with intermediate-risk non-muscle-invasive bladder cancer harboring FGFR alterations. Dr. Li explains that TAR-210, administered via a quick in-office procedure, continuously releases e...
|
